Skip to main content

Dianthus Therapeutics, Inc.

corporate_fare Company Profile

Dianthus Therapeutics, Inc.

DNTH·NASDAQ·Life Sciences·CIK 0001690585

We are a clinical-stage biotechnology company focused on developing therapies for severe autoimmune diseases. Our primary clinical-stage candidate is claseprubart, a monoclonal antibody engineered for an extended half-life, improved potency, and high selectivity for the active C1s complement protein. This design aims to allow for less frequent, convenient self-administered subcutaneous injections using a pre-filled pen. By selectively inhibiting the classical complement pathway, claseprubart may also reduce the risk of infection from encapsulated bacteria by preserving the immune activity of the lectin and alternative pathways. We believe claseprubart could address various complement-dependent diseases, offering potential improvements over existing and developing therapies in terms of efficacy, safety, or dosing convenience. Our second clinical-stage candidate, DNTH212, is a bifunctional fusion protein. It targets plasmacytoid dendritic cell BDCA2 to reduce Type 1 interferon production and simultaneously inhibits BAFF/APRIL to suppress B cell function. This approach targets both the innate and adaptive immune systems through two clinically validated pathways known to drive autoimmune disease, potentially addressing multiple autoimmune indications with improved outcomes. DNTH212 is also designed for convenient, infrequent, self-administered subcutaneous injections suitable for a pre-filled pen. Claseprubart, our most advanced product candidate, is a clinical-stage, highly potent, highly selective, and fully human monoclonal immunoglobulin G4 with picomolar binding affinity. It is designed to selectively bind only to the active form of C1s, which is generated during complement activation. C1s inhibition is a validated complement target in autoimmune and inflammatory fields, preventing the progression of the classical pathway cascade. Claseprubart incorporates YTE half-life extension technology, involving a specific three amino acid change in the Fc domain, and has a pharmacokinetic profile intended to support less frequent, lower dose, self-administration as a convenient subcutaneous injection.

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 23 items for DNTH at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-04, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 10/10, with 15 rated 8 or above. Recent SEC coverage for DNTH spans 8-K, 4, 144, 10-Q.

Recent high-impact activity:

  • Dianthus Q3: $1.2B Cash Into 2030, 75% CIDP Response Rate, MMN Data in December
  • Dianthus Posts $46.6M Q3 Loss, Touts 75% CIDP Response Rate and $1.2B Cash Into 2030
  • CEO Marino Garcia Sells $17.95M in Dianthus Stock Near 52-Week High
  • Officer Marino Garcia Files to Sell $13.6M in Dianthus Therapeutics Stock
  • Dianthus Posts $1.2B Cash, 75% CIDP Response Rate, and Advances gMG Phase 3

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$2.04M
Net Income
-$162.34M
Diluted EPS
-$4.20
Op. Cash Flow
-$129.06M
Free Cash Flow
-$129.27M
Operating Income
-$177.93M
Cash & Equivalents
$51.09M
Debt / Equity
0.00×
Net Margin
-79.73×
Shares Outstanding
43.22M sh
Source: 10-K · filed 2026-03-09 · accession 0001690585-26-000006

Short Interest & Short Volume

10.14 days to cover

FINRA reported short interest of 9,276,833 shares in DNTH as of the October 30, 2026 settlement, a 3.2% increase from the prior period — about 10.1 days to cover at its recent average daily volume. On November 20, 2026, 73.2% of DNTH volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)9,276,833 shares as of October 30, 2026
Change vs prior period▲ 3.2%
Days to cover10.14 at avg daily volume of 914,517
Daily short volume (FINRA facilities)73.2% of 231,200 shares on November 20, 2026
5-day average short volume60.9%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Moderate risk

Filing-implied dilution signals for DNTH, detected from its recent SEC filings · based on capital-structure filings through 2026-09-18.

ATM program1 shelf registration

New $500M ATM Program Established · Replaces Prior Shelf Capacity

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with D →
$84.08 -0.56% today
52-week range · as of 2026-11-04 $32.42 – $117.88
Market cap
$4.76B
Volume
799.7K (0.9× avg)
3-mo avg 910.9K
Live data · 2026-11-22 03:35 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed DNTH - Latest Insights

DNTH
Nov 04, 2026, 4:03 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $85.81
Real-time Price: $84.08 info
Change: -$1.73 (-2%) info
Market Cap: $4.761B info
DNTH
Nov 04, 2026, 4:01 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $85.81
Real-time Price: $84.08 info
Change: -$1.73 (-2%) info
Market Cap: $4.761B info
DNTH
Aug 07, 2026, 6:30 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $108.92
Real-time Price: $84.08 info
Change: -$24.84 (-23%) info
Market Cap: $4.761B info
DNTH
Aug 07, 2026, 4:18 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $108.92
Real-time Price: $84.08 info
Change: -$24.84 (-23%) info
Market Cap: $4.761B info
DNTH
Aug 04, 2026, 4:08 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $111.00
Real-time Price: $84.08 info
Change: -$26.92 (-24%) info
Market Cap: $4.761B info
DNTH
Aug 04, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $111.00
Real-time Price: $84.08 info
Change: -$26.92 (-24%) info
Market Cap: $4.761B info
DNTH
Aug 04, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $106.01
Real-time Price: $84.08 info
Change: -$21.93 (-21%) info
Market Cap: $4.761B info
DNTH
Jun 12, 2026, 7:03 AM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $76.45
Real-time Price: $84.08 info
Change: +$7.63 (+10%) info
Market Cap: $4.761B info
DNTH
Jun 12, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $76.45
Real-time Price: $84.08 info
Change: +$7.63 (+10%) info
Market Cap: $4.761B info
DNTH
May 05, 2026, 4:11 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $90.24
Real-time Price: $84.08 info
Change: -$6.16 (-7%) info
Market Cap: $4.761B info
DNTH
May 05, 2026, 4:06 PM EDT
Filing Type: 10-Q
Importance Score:
10
Price at Filing: $90.24
Real-time Price: $84.08 info
Change: -$6.16 (-7%) info
Market Cap: $4.761B info
DNTH
Mar 26, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $79.61
Real-time Price: $84.08 info
Change: +$4.47 (+6%) info
Market Cap: $4.761B info
DNTH
Mar 13, 2026, 8:40 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $77.80
Real-time Price: $84.08 info
Change: +$6.28 (+8%) info
Market Cap: $4.761B info
DNTH
Mar 12, 2026, 7:20 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $86.14
Real-time Price: $84.08 info
Change: -$2.06 (-2%) info
Market Cap: $4.761B info
DNTH
Mar 11, 2026, 5:28 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $87.00
Real-time Price: $84.08 info
Change: -$2.92 (-3%) info
Market Cap: $4.761B info
DNTH
Mar 10, 2026, 10:56 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $87.50
Real-time Price: $84.08 info
Change: -$3.42 (-4%) info
Market Cap: $4.761B info
DNTH
Mar 10, 2026, 9:54 PM EDT
Filing Type: S-3MEF
Importance Score:
8
Price at Filing: $83.14
Real-time Price: $84.08 info
Change: +$0.945 (+1%) info
Market Cap: $4.761B info
DNTH
Mar 09, 2026, 5:25 PM EDT
Filing Type: 424B5
Importance Score:
9
Price at Filing: $76.75
Real-time Price: $84.08 info
Change: +$7.33 (+10%) info
Market Cap: $4.761B info
DNTH
Mar 09, 2026, 4:01 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $75.26
Real-time Price: $84.08 info
Change: +$8.82 (+12%) info
Market Cap: $4.761B info
DNTH
Mar 09, 2026, 7:21 AM EDT
Filing Type: 10-K
Importance Score:
9
Price at Filing: $75.78
Real-time Price: $84.08 info
Change: +$8.30 (+11%) info
Market Cap: $4.761B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets